Back to Results
First PageMeta Content
Ranibizumab / Vascular endothelial growth factor / Bevacizumab / Macular degeneration / Macular edema / Diabetic retinopathy / Laser coagulation / Off-label use / Retina / Medicine / Ophthalmology / Health


Public Summary Document – November 2014 PBAC Meeting 6.2 AFLIBERCEPT 4 mg/0.1 mL injection, 1 x 0.1 mL vial,
Add to Reading List

Document Date: 2015-03-16 01:05:14

Open Document

File Size: 992,53 KB

Share Result on Facebook

City

Campochiaro / /

Company

AMD / DRCR.net / Aiello LP / GE / Bayer Australia Ltd. / Thach AB / Vinci / /

Event

FDA Phase / Judicial Event / /

Facility

Consumer Comments facility / /

IndustryTerm

literature search / telephone application / /

MedicalCondition

diabetic retinopathy / Macular Edema / central retinal vein occlusion / diabetes / diabetic retinopathy study / Diabetic Macular Edema / age-related macular degeneration / Low Vision / MS / blindness / /

MedicalTreatment

laser therapy / laser treatment / /

MusicAlbum

RESTORE / VISTA / /

OperatingSystem

Microsoft Vista / /

Organization

Department of Human Services / PBAC Meeting Administrative Advice Authority / Human Services Authority / Complex Drugs Unit / Intravitreal Administration of VEGF Trap-Eye / Department of Human Services Prior Written Approval of Complex Drugs Reply Paid / Department of Human Services Any / Repeated Intravitreal Administration / Medicare / /

Person

Mitchell O. Restore / /

/

Position

Manufacturer GENERAL / Direct head / Governor / Chief Executive / Nurse / General / /

Product

Triamcinolone / DV / Lucentis / 2Q8 / aflibercept / /

ProgrammingLanguage

FL / /

ProvinceOrState

Maryland / Florida / /

PublishedMedium

The READ 2 American Journal / Ophthalmology / /

Technology

laser / tomography / evaluation Trial ID Protocol / /

URL

www.humanservices.gov.au / /

SocialTag